PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2010; 5(8): e12358.
Published online 2010 August 23. doi:  10.1371/journal.pone.0012358
PMCID: PMC2925949

Paeonol Oxime Inhibits bFGF-Induced Angiogenesis and Reduces VEGF Levels in Fibrosarcoma Cells

Robert E. Means, Editor

Abstract

Background

We previously reported the anti-angiogenic activity of paeonol isolated from Moutan Cortex. In the present study, we investigated the negative effect of paeonol oxime (PO, a paeonol derivative) on basic fibroblast growth factor (bFGF)-mediated angiogenesis in human umbilical vein endothelial cells (HUVECs) (including tumor angiogenesis) and pro-survival activity in HT-1080 fibrosarcoma cell line.

Methodology/Principal Findings

We showed that PO (IC50  = 17.3 µg/ml) significantly inhibited bFGF-induced cell proliferation, which was achieved with higher concentrations of paeonol (IC50 over 200 µg). The treatment with PO blocked bFGF-stimulated migration and in vitro capillary differentiation (tube formation) in a dose-dependent manner. Furthermore, PO was able to disrupt neovascularization in vivo. Interestingly, PO (25 µg/ml) decreased the cell viability of HT-1080 fibrosarcoma cells but not that of HUVECs. The treatment with PO at 12.5 µg/ml reduced the levels of phosphorylated AKT and VEGF expression (intracellular and extracelluar) in HT-1080 cells. Consistently, immunefluorescence imaging analysis revealed that PO treatment attenuated AKT phosphorylation in HT-1080 cells.

Conclusions/Significance

Taken together, these results suggest that PO inhibits bFGF-induced angiogenesis in HUVECs and decreased the levels of PI3K, phospho-AKT and VEGF in HT-1080 cells.

Introduction

Angiogenesis in embryonic development, reproduction and wound healing is tightly regulated by the balance between the angiogenic inhibitors and activators [1], [2], [3], [4]. The obligatory dependence of solid tumor growth and progression on angiogenesis are well supported and accepted [5]. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) have been well documented as angiogenic activators [6], [7], [8]. While VEGF is a primary mediator of angiogenic responses, bFGF is also one of potent angiogenesis inducers to stimulate the vascular endothelial mitogenesis and is often involved in pathologic angiogenesis. bFGF is routinely employed as angiogenic polypeptide for experimental studies [9].

Tumor angiogenesis involves complex and multiple vascular endothelial responses as well as contributions from tumor cells. The endothelial responses include angiogenic factor-stimulated changes in the vascular endothelial permeability, degradation of the basement membrane by metalloproteases, migration, remodeling and proliferation of endothelial cells to form capillary tubes, and other processes. On the other hand, tumor cells or host stromal cells express VEGF induced by hypoxia and other autocrine or paracrine growth factors [2], [3], [4], [6], [7], [8], [9] to stimulate endothelial progenitor cells for angiogenesis. Interruptions of one or more steps in these processes can negatively affect angiogenesis and inhibit early malignant lesions to lower the cancer risk [10] VEGF expression is mediated by the phosphoinositide 3-kinase (PI3K) pathway in endothelial cells [11]. Also, PI3K pathway reveals its effects through its downstream kinase AKT to regulate various cellular processes including angiogenesis [12].

Paeonol oxime (1-[2-hydroxy-4-methoxy phenyl] ethanone oxime; PO) was derived from paeonol (2-hydroxy, 4-methoxy acetophenone), which has been shown to be anti-angiogenic [13] (Fig. 1). We designed and synthesized PO so that it also shares some similarity with acetylsalicylic acid (Fig. 1), a well known anti-inflammatory pain killer but also with anti-angiogenic activity [1], [14], with the goal to achieve better solubility and anti-angiogenic potency than paeonol. In this regard, we tested the anti-angiogenic properties of PO on bFGF-stimulated human umbilical vein endothelial cells (HUVECs) by examining proliferation, migration, tube formation and chick chorioallantoic membrane (CAM). We also explored the potential signaling events affected by PO in angiogenic HT-1080 cells by Western blotting and immunofluorescence microscopy.

Figure 1
Chemical structure of paeonol oxime.

Results

PO inhibited bFGF-induced proliferation of HUVECs

The cytotoxicity of PO against non-proliferating HUVECs (absence of angiogenic factors) was first tested to define the range of non-toxic concentrations of PO for in vitro angiogenesis experiments. As shown in Fig. 2A, after 24 h incubation, PO decreased MTT metabolizing ability (metabolic viability) of HUVECs in a concentration-dependent manner, with less than 20% decrease at up to 50 µg/ml of PO. All subsequent angiogenesis experiments were carried out at even lower concentrations (6.25, 12.5 or 25 µg/ml) to make sure of absence of significant cell death in the assays. Consistent with the results of cytotoxicity assay, 5-bromo-2′-deoxyuridine (BrdU) proliferation assay further confirmed non-toxic effect of PO in HUVECs (Fig. 2B).

Figure 2
PO inhibits bFGF-induced proliferation of HUVECs.

Since angiogenic factor-stimulated endothelial cell proliferation is a key step of the angiogenic processes [7], the effect of PO on bFGF (10 ng/ml) induced mitogenic response in HUVECs at non-toxic concentrations was analyzed. PO significantly inhibited bFGF-induced proliferation of HUVECs with IC50 of 17.3 µg/ml (Fig. 2C). In comparison, the parental compound paeonol suppressed bFGF-induced proliferation of HUVECs with an IC50 expected to be over 200 µg/ml (Fig. 2D). The marked difference observed here between PO and paeonol rendered further evaluation of the impact of PO on more of the endothelial responses induced by bFGF.

PO inhibited bFGF-induced migration and tube formation of HUVECs

To explore the effects of PO on bFGF-stimulated angiogenesis, the migration assay using the Boyden chamber was performed. As shown in Fig. 3A, cell motility of HUVECs was increased by 10.9-fold after bFGF treatment as compared with untreated control. In contrast, PO significantly inhibited bFGF-induced migration of HUVECs, in a concentration-dependent manner with IC50 of 5.3 µg/ml.

Figure 3
PO inhibits bFGF-induced migration and tube formation of HUVECs.

It is known that HUVECs undergo extensive in vitro differentiation to form capillary-like tubes on the Matrigel and bFGF stimulates this process [5]. In our experiments, PO significantly inhibited bFGF-induced tube formation by HUVECs, with IC50 of 6.2 µg/ml (Fig. 3B). Together, these data demonstrated that PO was able to inhibit critical processes involved in angiogenic responses.

PO disrupted bFGF-induced angiogenesis in CAM assay

To confirm the anti-angiogenic potential of PO, chick CAM assay was employed in the physiological context of vascular endothelial cells within intact vessels. As shown in Fig. 4, the treatment with bFGF (100 ng/embryo) resulted in a 2.6-fold increase of new blood vessels under the thermonox disc applied on the CAMs. Furthermore, PO treatment at both doses of 0.25 and 0.5 µg/egg almost totally nullified bFGF-induced angiogenesis without apparent thrombosis and hemorrhage.

Figure 4
PO disrupts bFGF-induced angiogenesis in vivo.

PO downregulated the expression of VEGF and PI3K/AKT signaling in HT-1080 cells

The effect of PO on human HT-1080 fibrosarcoma cells (a highly angiogenic cancer cell line) was investigated. Interestingly, PO, at 20 µg/ml, induced apparent cytotoxicity in the HT-1080 fibrosarcoma cells but not in normal mouse embryonic fibroblasts (MEF) (Fig. 5A). This decrease in cell viability upon PO treatment was also concentration dependent (Fig. 5A). Since 20 µg/ml PO did not induce apparent cytotoxicity in non-proliferating HUVECs either (Fig. 2A), the result suggests that besides roles in angiogenesis, PO at certain concentration might selectively affect viability of certain tumor cells.

Figure 5
PO downregulates the expression of VEGF and the PI3K/AKT signaling in HT-1080 cells.

Since VEGF is a crucial mediator of angiogenesis, we examined whether PO affects the expression of VEGF in HT-1080 cells. PO at 12.5 µg/ml significantly reduced not only the level of the secretion (Fig. 5B) its but also the expression of VEGF (Fig. 5C).

PI3K/AKT pathway is known to play a crucial role in angiogenic responses [15], [16]. Thus, we examined the potential role of PO on activation of PI3K and AKT in HT-1080 cells. As shown in Fig. 5C, PO at 12.5 µg/ml led to the decreased expression of PI3K and phosphorylation of its downstream target AKT. In order to confirm the ability of PO to inhibit PI3K/AKT pathway, a PI3K inhibitor LY294002 was also used as a positive control for inhibiting PI3K/AKT signaling in HT-1080 cells. As expected, LY294002 significantly suppressed AKT phosphorylation and VEGF expression similar to PO treatment (Fig. 5D). This was further verified by the immunofluorescence microscopy of HT-1080 cells in presence and absence of LY294002 and PO treatment (Fig. 5E).

To further confirm that the effects of PO on HT-1080 cells are due to its action on angiogenic properties, in vitro tube formation assay was carried out in the cells with or without the treatment with PO for 24 h (Fig. 6). The culture medium (CM) from HT-1080 cells induced HUVEC tube formation compared with that from untreated control cells (lanes 1 and 4). In contrast, less than half of PO-treated cells grown in CM (>47%) were able to induce HUVEC tube formation, than that cultured in CM alone (lanes 4 and 5), suggesting that PO is a potent anti-angiogenic agent. LY294002 was also prevented the tube formation (lane 6). VEGF and bFGF served as positive controls (lanes 2 and 3). However, PO had no significant effect on HT-1080 mediated cell proliferation and VEGF secretion in HUVECs (data not shown).

Figure 6
PO inhibits the tube formation of HUVECs induced by culture supernatants of HT-1080 cells.

Discussion

Paeonol was reported to have multi-biological activities such as anti-inflammatory [17], [18], anti-allergic [19], anti-tumor [20], anti-angiogenic [13] and anti-oxidant [21], [22] activities. In the present study, PO was synthesized from paeonol with an anticipation of improved solubility and increased anti-angiogenic potential based on the similarity of PO to aspirin. Assays based on HUVECs clearly demonstrated the improved anti-proliferative activity of PO compared with paeonol. Specifically, PO inhibited bFGF-induced proliferation of HUVECs with IC50 of 17.3 µg/ml, indicating that PO is more potent to inhibit cell proliferation than paeonol (IC50 >200 µg/ml). Also, PO suppressed HUVEC motility and tube formation in a concentration dependent manner and with similar potency (i.e., IC50 = 6.2 µg/ml). Consistently, PO significantly disrupted the neovascularization in bFGF-treated CAM of developing embryos in vivo. Furthermore, PO was effective at dosage of 0.25 and 0.5 µg per egg, more sensitive than paeonol, which was effective at 0.8 and 1.6 µg per egg.

Interestingly, PO displayed cytotoxicity against HT-1080 cells more effectively than HUVECs and MEFs, indicating a possible selectivity of PO to kill tumor cells over normal cells. It is possible that the cytotoxicity of PO against HT-1080 observed in Fig. 5A could also be due to/associated with the inhibition of PI3K/AKT signaling (Fig. 5D). In future, we plan to further study more of this interesting phenomenon and what it might implicate in potential clinical interventions. In terms of the molecular mechanisms responsible for anti-angiogenic response, VEGF production promotes the carcinogenic progression of cancer cells [23], [24], and VEGF is an important cytokine involved in both vasculogenesis and angiogenesis [25]. We observed that PO inhibited extracellular production and intracellular expression of VEGF in HT-1080 cells. These suggest PO would be able to suppress angiogenic processes in HT-1080 cancer cells as well as in human endothelial cells, especially considering that it has been reported that HT-1080 cell-secreted VEGF, promoted the basement membrane degradation, migration, proliferation and tube formation of endothelial cells [26], although we have not explored further on this due to our focus of study on HUVEC angiogenesis in this report. In other words, the downregulation of VEGF signaling by PO observed in HT-1080 cells is likely to lead to inhibition on angiogenesis of fibrosarcoma.

PI3K/AKT pathway has been known to stimulate angiogenesis [27], [28]. Arbiser et al. reported that Solenopsin, the alkaloidal component of the fire ant, prevented angiogenesis by inhibiting the activation of PI3K and the phosphorylation of AKT [29]. Nakashio et al. also reported that Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-AKT signaling pathway [30]. Similarly, we also showed that PO reduced the expression of PI3K, subsequently downregulated the phosphorylation of AKT, and VEGF secretion in HT-1080 sarcoma cells. A PI3K inhibitor LY294002 significantly suppressed AKT phosphorylation and VEGF expression, which is similar to PO treatment, implying that PI3K is related to and downstream of VEGF in the cells. Furthermore, the results from in vitro capillary tube formation assay, indicated that PO is able to inhibit HT-1080-mediated tube formation. Since LY294002 also had a similar inhibitory effect on tube formation in the same cells, it suggests that PO exerts its anti-angiogenic activity, possibly via VEGF/PI3KAKT pathway. Further studies are under way to examine whether PO-mediated anti-angiogenic activity is associated with this signaling pathway in HUVEC and cancer cells.

In summary, we demonstrated that PO inhibited bFGF-stimulated proliferation, migration, tube formation in human endothelial cells and also disrupted in vivo neovascularization. We also showed that PO suppressed PI3K/AKT signaling and reduced VEGF secretion and expression fibrosarcoma HT-1080 cells, which is consistent with the current understanding of the role of VEGF/PI3K in angiogenesis. The results from tube formation assay further indicate the anti-tumor angiogenic effect of PO. Based on our study, PO appears to be a promising angiogenic inhibitor and applicable to angiogenesis related diseases. Our data also suggested that PI3K is an intracellular target of PO to for achieving its inhibition on angiogenesis.

Materials and Methods

Paeonol oxime

Paeonol oxime (1-[2-hydroxy-4-methoxy phenyl] ethanone oxime, PO; molecular weight: 213) was synthesized from paeonol (Fig. 1A). Paeonol, hydroxyl ammonium and pyridine in anhydrous ethanol were stirred for 24 h under reflux and the reaction mixture was concentrated by Rotary evaporator. The resulting residue was purified by column chromatography. PO was more soluble as compared with paeonol due to the extra hydroxyl radical.

Cell culture

Human HT-1080 fibrosarcoma cells (ATCC CCL-121) were purchased from ATCC (Rockville, MD). The cells were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 units/ml of antibiotic-antimycotics. HUVECs were isolated from fresh human umbilical cord veins according to a published protocol [31] and cultured in M199 supplemented with 20% heat-inactivated FBS, 3 ng/ml bFGF, 5 units/ml heparin and 100 units/ml antibiotic-antimycotic in 0.1% gelatin coated flasks. HUVECs were used in passages three to six.

Cytotoxicity assay

MTT [3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was performed to determine the cytotoxicity of paenol oxime against non-proliferative HUVECs, mouse embryonic fibroblast (MEF) and HT-1080 cells [2]. Briefly, cells were seeded into 96-well plates at a density of 1×104 cells per well, grown in presence of various concentrations (0 ~120 µg/ml) of PO for 24 h. MTT solution (1 mg/ml) was added to each well and incubated at 37°C for 4 h. The medium was removed, and formazan formed was solubilized with DMSO and the absorbance at 570 nm measured by a microplate reader (Molecular Devices Co., Sunnyvale, CA). The percentage of viable cells was estimated compared with untreated control.

Proliferation assay

Cell proliferation assay was performed using a 5-bromo-2′-deoxyuridine (BrdU) colorimetric assay kit according to the manufacturer's instructions. HUVECs (3×103 cells/well) were seeded into 0.1% gelatin-coated 96-well plates and incubated in a humidified incubator for 24 h. Cells were starved for 6 h in M199 containing 5% heat-inactivated FBS and then treated with various concentrations of PO or paeonol in the absence or presence of bFGF (10 ng/ml) in M199 containing 5% heat-inactivated FBS and 5 units/ml heparin at 37°C for 48 h. Cells were added with BrdU for additional 6 h, fixed with FixDenat solution for 30 min and incubated with anti-BrdU followed by the horseradish peroxidase reaction. The reaction was terminated by addition of 25 µl of 1 M H2SO4 and the absorbance was measured using a microplate reader (Molecular Devices Co., Sunnyvale, CA) at 450 nm–690 nm. IC50 of PO paeonol was calculated with GraphPad Prism 5.0 software.

Migration assay

The motility of HUVECs to pass through gelatin-coated filters was measured by using the Boyden chamber (Nuero Probe, Inc., Cabin John, MD). Briefly, polyester membrane (12 µm pores) was coated with 0.1% gelatin for 30 min and dried. The lower chamber was filled with 30 µl of M199 containing 0.5% BSA in the presence or absence of bFGF (10 ng/ml). The coated membrane and upper chamber were laid over the lower chamber. HUVECs (5×104 cells/well) were plated onto the upper chamber with or without various concentrations of PO and incubated for 6 h at 37°C in a 5% CO2 incubator. After incubation, the membrane was fixed with Diff-Quick fixative and stained with Diff-Quick Solution I and II (DADE Behring Inc., Newark, DE). The magnitude of the migrated cells was evaluated by counting the migrated cells in 2 random high-power (×100) microscope fields per well under an Axiovert S 100 light microscope (Carl Zeiss Inc., Weimar, Germany) at ×100 magnification.

In vitro tube formation assay

Tube formation assay was performed using growth factor reduced Matrigel as previously described [3], [4], [32]. HUVECs (7×104 cells) were seeded onto growth factor reduced Matrigel-coated 24-well plates and treated with or without various concentrations of PO in M199 with 1% FBS, 10 ng/ml bFGF and 5 units/ml heparin for 24 h at 37°C, or culture medium (CM) from HT-1080 cells treated with or without PO treatment. The cells were fixed with Diff-Quick solution and visualized under an Axiovert S 100 light microscope (Carl Zeiss Inc., Weimar, Germany) in 3 random high-power (×100) microscope fields per well. The number of circular tubules was counted by using Image-Pro® Plus 4.5 (Media CyberMetics Inc., Bethesda, MD) software.

Chick chorioallantoic membrane (CAM) assay

In vivo anti-angiogenic activity of PO was assessed using CAM assay as described previously [32]. Briefly, PO and bFGF (100 ng) were loaded onto a 1/4 piece of thermonox disc (Nunc, Naperville, IL). The dried thermonox disc was applied to the CAM of a 9-day-old embryo and incubated for 48 h. Then fat emulsion was injected under the CAM for better visualization of the blood vessels. The number of newly formed blood vessels was counted. The experiment was repeated twice with 15 eggs per group.

Enzyme linked immunosorbent assay (ELISA) for VEGF

ELISA was performed using Biosource Human Vascular Endothelial Growth Factor ELISA kit (Biosource International Inc., Camarillo, CA), following manufacturers' instructions. The minimum detectable dose of VEGF is <5 pg/ml, and 100% cross-reactivity with human VEGF-121 and complete parallelism with human VEGF-165. Percentages of coefficient of variation CV) in intra- and inter-assay were 3.7–5.5% and 6.5–9.3%, respectively. All samples were within the dynamic range of the standard curve.

Western blot analysis

Cell lysate preparation and immunoblotting were as described previously [3], [32]. In brief, HT-1080 cells were lyzed in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, supplemented with protease inhibitors (10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin A, and 1 mM of 4-(2-aminoethyl) benzenesulfonyl fluoride) and phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4). The extracts were incubated on ice for 20 min, centrifuged at 14000× g for 20 min at 4°C and supernatants were collected. Protein conntraions were determined by Bradford assay (Bio-Rad), and proteins were separated by electrophoresison SDS-polyacrylamide gels and transferred to Hybond-C nitrocellulose membranes at 300 mA for 2 h. Membranes were blocked with 5% nonfat dry milk in TBS-T (0.05% Tween-20, 138 mM NaCl, and 25 mM Tris base). Protein expression was determined using antibodies against VEGF (Santa Cruz Biotechnologies, Santa Cruz, CA), P13K, phospho-AKT, AKT (Cell Signaling Technology, Danvers, MA) and β-actin (Sigma, St. Louis, MO). The blots were incubated with horseradish peroxidase-conjugated antibodies and detected by enhanced chemiluminescence (ECL) detection system.

Immunofluorescence microscopy

HT-1080 cells were fixed on poly-L-lysine coated slides in 4% paraformaldehyde and then permeabilized in cold methanol. Cells were then incubated with 10% normal goat serum in PBS for 1 h, followed by immunostaining with rabbit polyclonal phospho-AKT antibody (Cell Signaling Technology, Danvers, MA). Rabbit IgG fluorescein isothiocyanate (FITC) antibody H & L (Abcam, Cambridge, MA) was used as the secondary antibody. The immunostained cells were mounted in medium containing DAPI (Vectashield, Vector Labs, Burlingame, CA) and visualized under a Carl Zeiss LSM5 confocal microscope.

Statistical analysis

All data were presented as mean ± standard deviation (S.D.). The statistically significant differences between control and PO treated groups were calculated by Student's t-test.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (No. 2009-0063466). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene. 2006;25:122–129. [PubMed]
2. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63. [PubMed]
3. Lee HJ, Lee EO, Rhee YH, Ahn KS, Li GX, et al. An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. Carcinogenesis. 2006;27:2455–2463. [PubMed]
4. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, et al. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell. 1989;58:933–943. [PubMed]
5. Lee HJ, Song GY, Li G, Lee JH, Lu J, et al. 6-(1-Oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits lewis lung cancer by antiangiogenesis and apoptosis. Int J Cancer. 2007;120:2481–2490. [PubMed]
6. Lee HJ, Lim ES, Ahn KS, Shim BS, Kim HM, et al. Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator. Biol Pharm Bull. 2005;28:27–31. [PubMed]
7. Bicknell R. Vascular targeting and the inhibition of angiogenesis. Ann Oncol. 1994;5(Suppl 4):45–50. [PubMed]
8. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–1149. [PubMed]
9. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–2392. [PubMed]
10. Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. Recent Results Cancer Res. 2010;180:51–81. [PubMed]
11. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A. 2000;97:1749–1753. [PubMed]
12. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39. [PubMed]
13. Kim SA, Lee HJ, Ahn KS, Lee EO, Choi SH, et al. Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. Biol Pharm Bull. 2009;32:1142–1147. [PubMed]
14. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 2006;20:2009–2016. [PubMed]
15. Shankar S, Chen Q, Srivastava RK. Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal. 2008;3:7. [PMC free article] [PubMed]
16. Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156:141–150. [PubMed]
17. Chou TC. Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br J Pharmacol. 2003;139:1146–1152. [PMC free article] [PubMed]
18. Huang H, Chang EJ, Lee Y, Kim JS, Kang SS, et al. A genome-wide microarray analysis reveals anti-inflammatory target genes of paeonol in macrophages. Inflamm Res. 2008;57:189–198. [PubMed]
19. Kim SH, Kim SA, Park MK, Park YD, Na HJ, et al. Paeonol inhibits anaphylactic reaction by regulating histamine and TNF-alpha. Int Immunopharmacol. 2004;4:279–287. [PubMed]
20. Chunhu Z, Suiyu H, Meiqun C, Guilin X, Yunhui L. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells. Anticancer Drugs. 2008;19:401–409. [PubMed]
21. Zhang G, Yu Z, Zhao H. [Protective effect of paeonol on repeated cerebral ischemia in rats]. Zhong Yao Cai. 1997;20:626–628. [PubMed]
22. Hsieh CL, Cheng CY, Tsai TH, Lin IH, Liu CH, et al. Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats. J Ethnopharmacol. 2006;106:208–215. [PubMed]
23. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001;84:1610–1615. [PMC free article] [PubMed]
24. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001;8:260–267. [PubMed]
25. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29:10–14. [PubMed]
26. Ito Y, Iwamoto Y, Tanaka K, Okuyama K, Sugioka Y. A quantitative assay using basement membrane extracts to study tumor angiogenesis in vivo. Int J Cancer. 1996;67:148–152. [PubMed]
27. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell. 2005;16:4153–4162. [PMC free article] [PubMed]
28. Shi YH, Wang YX, Bingle L, Gong LH, Heng WJ, et al. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol. 2005;205:530–536. [PubMed]
29. Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, et al. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood. 2007;109:560–565. [PubMed]
30. Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer. 2002;98:36–41. [PubMed]
31. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745–2756. [PMC free article] [PubMed]
32. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, et al. Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis. 2005;26:1436–1445. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science